Does BNP testing aid diagnosis of heart failure?

Drug and Therapeutics Bulletin

Volumn 47, Issue 10, 2009, Pages 110-113

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGE; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIET; DISEASE MARKER; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EXERCISE; HEART FAILURE; HUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREDICTION; REVIEW; SEX DIFFERENCE; UNITED KINGDOM; BLOOD; COST BENEFIT ANALYSIS; ECONOMICS; LABORATORY DIAGNOSIS; RISK; SENSITIVITY AND SPECIFICITY; SODIUM INTAKE;

AGE FACTORS; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; COST-BENEFIT ANALYSIS; EXERCISE; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; PEPTIDE FRAGMENTS; PRACTICE GUIDELINES AS TOPIC; SENSITIVITY AND SPECIFICITY; SEX FACTORS; SODIUM, DIETARY; SPECIMEN HANDLING;

EID: 77649210326     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2009.09.0042     Document Type: Review

References (23)

1. National Institute for Clinical Excellence, 2003. Chronic heart failure. Management of chronic heart failure in adults in primary and secondary care. Clinical guideline 5 [online]. Available: http://www.nice.org.uk/ nicemedia/pdf/CG5NICEguideline.pdf (Accessed 22 September 2009)
2. Scottish Intercollegiate Guidelines Network, 2007. Management of chronic heart failure. A national clinical guideline [online]. Available:http://www.sign.ac.uk/pdf/sign95.pdf (Accessed 22 September 2009).
3. Dickstein K et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-442.
4. Mant J et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. NHS Health Technol Assess 2009; 13 (32).
5. Begg A. Heart failure indicators for QOF 2009/10 reflect latest evidence [online]. Available: http://www.eguidelines.co.uk/eguidelinesmain/gip/vol-12/ jun-09/begg-qof-jun09.php [Accessed 22 September 2009].
6. Department of Health, 2009. Archive - Commissioner based monthly diagnostics [online]. Available: http://www.dh.gov.uk/en/ Publicationsandstatistics/Statistics/Performancedataandstatistics/ HospitalWaitingTimesandListStatistics/ Diagnostics/DH-087009 [Accessed 22 September 2009].
7. Mair J. Biochemistry of B-type natriuretic peptide - where are we now? Clin Chem Lab Med 2008; 46: 1507-14.
8. Cowie MR et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003; 24: 1710-8.
9. Personal communication. Alan Reid, Scheme Organiser, UK NEQAS Cardiac Markers.
10. Ewald B et al. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Intern Med J 2008; 38: 101-13. doi:10.1136/bmj.326.7382.196.
11. Deeks JJ. Systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001; 323: 157-62.
12. Redfield MM et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002; 40: 976-82.
13. Penney MD. Natriuretic peptides and the heart: current and future implications for clinical biochemistry. Ann Clin Biochem 2005; 42: 432-40.
14. Lang CC et al. Dietary loading sodium increase plasma BNP. J Hypertens 1991; 9: 779-82.
15. Tsutamoto T et al. Effect of spironolactone on plasma natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. Journal of the American College of Cardiology 2001; 37: 1228-33.
16. Inoko M et al. Effect of angiotensin-converting enzyme inhibition on sympathetic tone in patients with mild to moderate heart failure. Jpn Circ J 2001; 65: 395-8.
17. Latini R et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: The Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002; 106: 2454-8.
18. Tsutamoto T et al. Digitalis increases brain natriuretic peptide in patients with severe congestive heart failure. American Heart Journal 1997; 134: 910-6.
19. Kato M et al. Augmented response in plasma brain natriuretic peptide to dynamic exercise in patients with left ventricular dysfunction and congestive heart failure. J Intern Med 2000; 248: 309-15.
20. McNairy M et al. Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: Implications for outpatient monitoring with B-type natriuretic peptide. Am Heart J 2001; 143: 406-11.
21. Murdoch DR et al. Brain natriuretic peptide is stable in whole blood and can be measured usng a simple rapid assay: implications for clinical practice. Heart 1997; 78: 594-7.
22. Clerico A et al. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP Immunoassays in chronic and acute heart failure: a systematic review. Clin Chem 2007; 53: 813-22.
23. British Heart Foundation, 2008. The role of B-type natriuretic peptide (BNP) in the management of heart failure [online]. Available: http://www.bhf.org.uk/publications/view-publication.aspx?ps=1000673 [Accessed 22 September 2009].